$KVUE

Kimberly-Clark seeks EU approval for its $40bn acquisition of Kenvue, aiming to create a consumer health and personal care giant with $32bn annual revenue. The deal, announced last November, targets $2.1bn in annual cost savings. EU regulators will assess competition concerns, with a decision pending. The acquisition would expand Kimberly-Clark's portfolio to include brands like Tylenol, Listerine, and Neutrogena.

Kimberly-Clark (KMB) has requested EU approval for its $40 billion acquisition of Kenvue, the maker of Tylenol. The deal, announced in November 2023, is expected to close in the second half of 2026. Kimberly-Clark anticipates $2.1 billion in annual cost savings and $32 billion in combined annual revenues, including Kenvue's brands like Listerine, Aveeno, and Neutrogena.

Kimberly-Clark (KMB) seeks EU antitrust approval for its $49B acquisition of Kenvue (KVUE), with a provisional deadline set for Sept. 29. The deal, approved by shareholders in January, still faces regulatory reviews in several jurisdictions, including China's Phase 2 examination. The companies aim to complete the transaction in Q4 2026, subject to approvals.

Essity's $284M acquisition of Kenvue's feminine-care business, including brands like Carefree and o.b., is under review by Brazil's competition authority. The deal is subject to regulatory approval.

Kenvue (KVUE) launched Zyrtec Allergen Shield Spray, a drug-free nasal mist that blocks allergens. The product extends Zyrtec's offerings beyond antihistamines, reflecting Kenvue's focus on proactive, drug-free allergy management. Kenvue projects $16.7B revenue and $2.3B earnings by 2029, aligning with its current valuation. The company recently increased its dividend to $0.21 per share, emphasizing shareholder returns while managing integration and restructuring efforts.

New Zealand approved Kimberly-Clark's acquisition of Kenvue, requiring the divestment of Kenvue's feminine hygiene brands (Carefree, Stayfree) in NZ and Australia. The move aims to prevent market concentration. Kimberly-Clark must sell the unit to an approved buyer to complete the deal.

Colgate-Palmolive India appointed Manish Anandani, former Kenvue executive, as CEO. Current CEO Prabha Narasimhan moves to a marketing role. The company focuses on e-commerce and premium products. Shares fell 1% on the news.

Kimberly-Clark (KMB) received approval from New Zealand’s Commerce Commission to acquire Kenvue, contingent on divesting Kenvue’s feminine hygiene business in NZ and Australia. The regulator cited competition concerns, requiring the sale to an approved buyer to maintain market competition. The deal is part of Kimberly-Clark’s global acquisition of Kenvue.

Kimberly-Clark's acquisition of Kenvue has been approved by New Zealand's antitrust regulator, subject to certain conditions. The deal is part of a global merger agreement between the two companies.

Colgate Palmolive India has named a Kenvue executive as its new Managing Director and CEO. The appointment is effective immediately, according to the company's announcement.